Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)

Pulmonary Arterial Hypertension Clinical Trial

— OPTIMA  

Official title:

Prospective, Multicenter, Open-label Study Evaluating the Effects of First-line Oral Combination Therapy of Macitentan and Tadalafil in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (OPTIMA).

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02968901
• Other study ID #: AC-055-405
• Status: Terminated
• Phase: Phase 4
• Start date: September 1, 2015
• Est. completion date: September 10, 2018

Study information

• Verified date: October 2019
• Source: Actelion
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to document the effect of first line dual oral combination therapy with macitentan 10mg and tadalafil 40mg on pulmonary vascular resistance (PVR) in treatment-naïve patients with newly diagnosed pulmonary arterial hypertension (PAH).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 46
• Est. completion date: September 10, 2018
• Est. primary completion date: September 10, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria :

1. Signed informed consent prior to any study-mandated procedure.

2. Male or female = 18 and = 75 years of age at screening.

3. Initial PAH diagnosis < 6 months prior to Day 1.

4. Right heart catheterization (RHC) performed between Day -28 and Day 1 (RHC data obtained at the study site within this time frame, but before the study, i.e., before signed informed consent, are acceptable), meeting all the following criteria:

• Resting mean pulmonary arterial pressure (mPAP) = 25 mmHg.

• Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) = 15 mmHg.

• PVR = 400 dyn·sec/cm5 (= 5 Wood units) if PCWP < 12 mmHg OR PVR = 500 dyn·sec/cm5 (= 6.25 Wood units) if PCWP in [12-15] mmHg.

• Negative vasoreactivity test mandatory in idiopathic PAH (at this or a previous RHC).

5. World Health Organization (WHO) Functional Class (FC) II to III.

6. PAH etiology belonging to one of the following groups:

• Idiopathic.

• Heritable.

• Anorexigens induced.

• Associated with one of the following:

• Connective tissue disease

• Congenital heart disease with simple systemic-to-pulmonary shunt (atrial septal defect, ventricular septal defect, patent ductus arteriosus) =1 year after surgical repair

• HIV infection

7. 6MWD = 50 m at screening.

8. Woman of childbearing potential [see definition in Section 4.5.1] must:

• Have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at the D1 visit, and

• Agree to perform monthly pregnancy tests up to 30 days after EOT2, and

• Agree to use reliable contraception [defined in Section 4.5.2] from screening up to 30 days after EOT2. Reliable contraception must be started at least 11 days prior to Day 1.

Exclusion Criteria:

1. Any PAH-specific drug therapy [e.g. any endothelin receptor antagonist, phosphodiesterase-5 inhibitors (PDE-5i), soluble guanylate cyclase stimulator, prostacyclin, prostacyclin analog, or prostacyclin receptor agonist] at any time prior to Day 1 (single-dose administration for vasoreactivity testing is permitted; previous iloprost used intermittently for the treatment of digital ulcers or Raynaud's phenomenon is permitted if stopped > 6 months prior to Day 1).

2. Subjects who changed the dose or discontinued calcium channel blockers within 1 week prior to Day 1.

3. Initiation of diuretics within 1 week prior to RCH.

4. Subjects on oral diuretics in whom the dose has not been stable for at least 1 week prior to RHC.

5. Treatment with other PDE-5i for erectile dysfunction.

6. Treatment with strong inducers of CYP3A4 (e.g., carbamazepine, rifampin, rifampicin, rifabutin, rifapentin, phenobarbital, phenytoin, and St. John's wort) = 28 days prior to Day 1.

7. Treatment with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, boceprevir, telaprevir, saquinavir, lopinavir, fosamprenavir, darunavir, tipranavir, atazanavir, nelfinavir, amprenavir, indinavir) = 28 days prior to Day 1.

8. History of priapism.

9. Significant aortic and mitral valve disease requiring a specific treatment.

10. Pericardial constriction.

11. Life-threatening arrhythmia.

12. Uncontrolled hypertension.

13. Symptomatic coronary artery disease.

14. Cardio-pulmonary rehabilitation program based on exercise (planned, or started = 12 weeks prior to Day 1).

15. Body mass index (BMI) > 40 kg/m2 at screening.

16. Acute myocardial infarction = 12 weeks prior to Day 1.

17. Known permanent atrial fibrillation.

18. Low blood pressure < 90/50 mmHg at screening or Day 1.

19. Ongoing or planned treatment with nitrates and/or doxazosin.

20. DLCO < 40% of predicted value (eligible only if no sign of veno-occlusive disease according to adjudication committee);

21. Presence of = 1 of the following signs of relevant lung disease at any time prior to Day 1:

• FEV1/FVC < 70% and FEV1 < 65% of predicted after bronchodilator administration;

• Total Lung Capacity (TLC) < 60% of predicted.

22. Known or suspicion of pulmonary veno-occlusive disease (PVOD).

23. Severe renal insufficiency (estimated creatinine clearance = 30 mL/min/1.73m²) assessed by central laboratory at screening.

24. Ongoing or planned dialysis.

25. Documented severe hepatic impairment (with or without cirrhosis) according to National Cancer Institute organ dysfunction working group criteria, defined as total bilirubin > 3 x ULN accompanied by AST > ULN (assessed by central laboratory at screening) and/or Child-Pugh Class C.

26. Serum AST and/or ALT > 3 x ULN (assessed by central laboratory at screening).

27. Porto-pulmonary hypertension.

28. Hemoglobin < 100 g/L assessed by central laboratory at screening.

29. Hypersensitivity to any active substance or excipient of macitentan or tadalafil formulation.

30. Loss of vision in one eye because of non-arteritic anterior ischemic optic neuropathy (NAION), regardless of whether or not this episode was in connection with previous PDE-5i exposure.

31. Hereditary degenerative retinal disorders, including retinitis pigmentosa.

32. Pregnancy, breast-feeding, intention to become pregnant during the study or woman of childbearing potential not agree to use reliable method of contraception from screening up to 30 days after EOT2.

33. Hereditary problems of galactose intolerance, Lapp lactase deficiency, glucosegalactose malabsorption.

34. Any factor or condition likely to affect protocol compliance of the patient as judged by the investigator.

35. Treatment with another investigational drug (planned, or taken = 12 weeks prior to Day 1).

36. Concomitant life-threatening disease with a life expectancy < 12 months.

Related Conditions & MeSH terms

• Familial Primary Pulmonary Hypertension
• Hypertension
• Pulmonary Arterial Hypertension

Intervention

Drug:
• macitentan
used in open label
• tadalafil
used in open label

Locations

Country	Name	City	State
France	Hôpital Jean Minjoz	Besançon
France	Hôpital de Haut Levêque	Bordeaux
France	Hôpital Côte de Nacre	Caen
France	CHU Site du Bocage	Dijon
France	Hôpital Albert Michallon	Grenoble
France	Hôpital Bicètre	Le Kremlin-Bicêtre
France	Hôpital Dupuytren	Limoges
France	Hôpital Louis Pradel	Lyon
France	Hôpital Timone Adultes	Marseille
France	Hôpital Arnaud de Villeneuve	Montpellier
France	CHR La Miletrie	Poitiers
France	Hôpital Robert Debré	Reims
France	Hôpital Pontchaillou	Rennes
France	Hôpital Charles Nicolle	Rouen
France	Hôpital Nord	Saint-Priest-en-Jarez
France	Hôpital Civil	Strasbourg
France	Hôpital Larrey	Toulouse
France	Hôpital Bretonneau	Tours

Sponsors (1)

Lead Sponsor	Collaborator
Actelion

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	pulmonary vascular resistance (PVR)	Change from Baseline to Week 16 in percentage of patients with clinically meaningful improvement of PVR (decrease of 30% from baseline to Week 16)	16 weeks
Secondary	mean right atrial pressure (mRAP)	Change from Baseline to Week 16 in mean right atrial pressure (mRAP)	Week 16
Secondary	6MWD	Change from Baseline to Week 16 in 6MWD	Week 16
Secondary	level NT-proBNP	Change in NT-proBNP from baseline to Week 16	Week 16
Secondary	mean pulmonary arterial pressure (mPAP)	Change from Baseline to Week 16 in mean pulmonary arterial pressure (mPAP)	Week 16
Secondary	cardiac index (CI)	Change from Baseline to Week 16 in cardiac index (CI).	Week 16
Secondary	total pulmonary resistance (TPR)	Change from Baseline to Week 16 in total pulmonary resistance (TPR)	Week 16
Secondary	mixed venous oxygen saturation (Sv02)	Change from Baseline to Week 16 in mixed venous oxygen saturation (Sv02)	Week 16
Secondary	WHO functional class	Change from baseline to Week 16 in WHO functional class and Percentage of patients with improvement/worsening of WHO functional class from baseline to Week 16	Week 16
Secondary	Number of treatment goals	Number of treatment goals (score 0 or 1 per goal, i.e. total score 0-5) met at Week 16: WHO-FC I or II; Cardiac index > 2.8 L/min/m²; mRAP < 8 mmHg; 6MWD > 400 m; NT-proBNP < 3xULN	Week 16

External Links

•   Clinical study evaluating the effects of first-line oral combination therapy of macitentan and tadalafil in patients with newly diagnosed pulmonary arterial hypertension (OPTIMA)